Beijing Peptide Biomedical Technology

Beijing Peptide Biomedical Technology, also known as Putaide, is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of innovative peptide-based therapeutics. The company leverages a proprietary technology platform focused on peptide sequence optimization and long-acting modifications to treat metabolic and endocrine disorders. Its research and development efforts are primarily centered on multi-target agonists, including dual and triple receptor agonists targeting GLP-1, GIP, and Glucagon receptors. These candidates are designed to provide superior efficacy in weight management and glycemic control for patients with obesity and type 2 diabetes. The company's lead program, PTD-001, is currently advancing through clinical trials, positioning Beijing Peptide as a significant player in the next generation of metabolic disease treatments.